» Articles » PMID: 29344262

Extract Suppresses Colorectal Cancer Growth Through Multiple Cellular Pathways

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Jan 19
PMID 29344262
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The development of colorectal cancer (CRC) is strongly associated with the imbalance of various intracellular signal transduction cascades, including protein kinase B (AKT), mitogen-activated protein kinase 1 (MAPK), signal transducer and activator of transcription 3 (STAT3), as well as crosstalk between these signaling networks. At present, anti-tumor agents are often single-targeted and therefore are not always therapeutically effective. Moreover, long-term use of these anti-tumor agents often generates drug resistance and potential side effects. These problems highlight the urgent need for the development of novel and more effective anti-cancer drugs. (HDW) has been used as a major component in traditional Chinese medicine for the clinical treatment of colorectal cancer, with a limited number of adverse effects. However, the molecular mechanisms, which underlie its anti-cancer activity, still require further elucidation. In the present study, using xenograft models and various different human CRC cell lines, the efficacy of the ethanol extract of HDW (EEHDW) against tumor growth was evaluated, and its underlying molecular mechanisms of action were investigated. It was demonstrated that EEHDW was able to inhibit cancer growth and . Furthermore, EEHDW was able to suppress the activation of several CRC-associated signaling pathways and was able to regulate the expression of various inflammatory and angiogenic factors. This resulted in the induction of apoptosis and inhibition of cellular proliferation, as well as tumor angiogenesis. The present study demonstrated that EEHDW is able to exhibit anti-cancer activity due to its ability to affect multiple intracellular targets, which suggests that it may be a novel multi-potent therapeutic agent for the treatment of colorectal cancer.

Citing Articles

Chinese herbal medicine for the treatment of intestinal cancer: preclinical studies and potential clinical applications.

Zhang J, Wu Y, Tian Y, Xu H, Lin Z, Xian Y Mol Cancer. 2024; 23(1):217.

PMID: 39354520 PMC: 11443726. DOI: 10.1186/s12943-024-02135-3.


The immunotherapy mechanism of Hedyotis Diffusae Herba in treating liver cancer: a study based on network pharmacology, bioinformatics, and experimental validation.

Zheng Q, Wu X, Peng S Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):951-965.

PMID: 39093467 DOI: 10.1007/s00210-024-03312-3.


Mechanism of Dahuang Mudan Decotion in the treatment of colorectal cancer based on network pharmacology and experimental validation.

Li X, Liu X, Yang F, Meng T, Li X, Yan Y Heliyon. 2024; 10(11):e32136.

PMID: 38882337 PMC: 11176830. DOI: 10.1016/j.heliyon.2024.e32136.


Phytochemistry, pharmacology, and medical uses of Oldenlandia (family Rubaceae): a review.

Al-Shuhaib M, Al-Shuhaib J Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):2021-2053.

PMID: 37837473 DOI: 10.1007/s00210-023-02756-3.


Network pharmacology and experimental validation to identify the potential mechanism of Hedyotis diffusa Willd against rheumatoid arthritis.

Deng H, Jiang J, Zhang S, Wu L, Zhang Q, Sun W Sci Rep. 2023; 13(1):1425.

PMID: 36697436 PMC: 9877023. DOI: 10.1038/s41598-022-25579-3.


References
1.
Garcia-Caballero M, Paupert J, Blacher S, Van de Velde M, Quesada A, Medina M . Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases. J Hematol Oncol. 2017; 10(1):122. PMC: 5477162. DOI: 10.1186/s13045-017-0484-1. View

2.
Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B . Colorectal cancer. Lancet. 2010; 375(9719):1030-47. DOI: 10.1016/S0140-6736(10)60353-4. View

3.
Eaden J, Abrams K, Mayberry J . The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48(4):526-35. PMC: 1728259. DOI: 10.1136/gut.48.4.526. View

4.
Popivanova B, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S . Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118(2):560-70. PMC: 2213370. DOI: 10.1172/JCI32453. View

5.
Jauch D, Martin M, Schiechl G, Kesselring R, Schlitt H, Geissler E . Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut. 2011; 60(12):1678-86. DOI: 10.1136/gutjnl-2011-300612. View